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Background:  Predictors  of  ventricular  arrhythmias  (VA)  in  patients  with  cardiac  sarcoidosis  (CS)  remain
unclear.
Methods  and  results:  We  examined  61 consecutive  CS  patients  who  were  admitted  to our hospital  from
April  2002  to March  2012 with  a mean  follow-up  period  of  45  ±  31  months  for the  relationship  between
delayed  enhancement  on cardiac  magnetic  resonance  imaging  (DE-MRI)  and  VA or a composite  end-
point,  including  VA,  heart  failure  hospitalization,  and  cardiovascular  mortality.  Although  there  was  no
signiﬁcant  difference  in baseline  clinical  characteristics  between  patients  with  VA  and  those  without  it,
the former  group  was  characterized  as compared  with the  latter  by  lower  left  ventricular  (LV)  ejection
fraction  (p  <  0.05),  larger  LV  systolic/diastolic  dimensions  (both  p < 0.05),  and  a signiﬁcant  associationrognosis
agnetic resonance imaging
with  DE-MRI  (p <  0.05).  Furthermore,  the  patients  with DE-MRI  (n =  26),  as  compared  with  those  with-
out  it (n = 11),  had  a signiﬁcantly  higher  composite  endpoint  event  rate  (41%  vs. 0%,  p <  0.05)  and  a  trend
toward  higher  VA  (29%  vs.  0%, p =  0.12).  Univariate  analysis  also  showed  that  impaired  LV  systolic  function
was  signiﬁcantly  associated  with  composite  events  on  follow-up.
Conclusions:  These  results  indicate  that  the presence  of  DE-MRI  is a signiﬁcant  predictor  of VA  events  and
poor  outcome  in  CS  patients.
2  Jap© 201
ntroduction
Sarcoidosis is a multisystem disease that is histologically char-
cterized by non-caseating granuloma formation in various organs
1]. Although sarcoidosis could affect any organ, including the
ungs, skin, eyes, liver, and lymphatics [1,2], cardiac involvement
s the most important prognostic factor [3,4]. The incidence of car-
iac sarcoidosis (CS) has been reported to be ∼2% among patients
ith sarcoidosis, however, previous autopsy studies demonstrated
hat cardiac involvement is relatively high (20–25%) [4,5], which
as been recently conﬁrmed by cardiac imaging [6].
CS frequently presents as asymptomatic cardiac involvement
nd is only evident by abnormalities on electrocardiography (ECG),
chocardiography, or magnetic resonance imaging (MRI) [2]. Clin-
cally, CS commonly presents with congestive heart failure and
ilated cardiomyopathy (DCM)-like manifestations associated with
∗ Corresponding author at: Department of Cardiovascular Medicine, Tohoku Uni-
ersity Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574,
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electrical abnormalities, including conduction disturbances [4] and
serious ventricular arrhythmias (VA), including ventricular tachy-
cardia (VT) and ventricular ﬁbrillation (VF) [7]. Indeed, sustained or
non-sustained VT (NSVT) has been noted in 23% of patients with CS,
where re-entry is the most common mechanism involving myocar-
dial scarring and ﬁbrosis areas [8].  Indeed, VF could account for the
majority of cases of sudden cardiac death (SCD) in CS patients [4].
Although CS in general and VA in particular are predictors of
poor outcome [3],  predictors of VA and adverse outcome in CS
patients remain to be identiﬁed.
In the present study, we  thus addressed this clinically important
issue in our CS patients, with focus on the role of delayed enhance-
ment on magnetic resonance imaging (DE-MRI) as a marker of poor
prognosis in general, and of this serious arrhythmia in particular in
this subset of patients.
MethodsPatient selection
We examined 61 consecutive patients who  were diagnosed as
having CS at our hospital or other referring hospitals in the Tohoku
vier Ltd. All rights reserved.
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Fig. 1. Delayed enhancement on cardiac magnetic resonance imaging (MRI) in a
cardiac sarcoidosis (CS) patient. Evidence of delayed gadolinium enhancement on
cardiac MRI  in the sub-epicardial layer of the anterior left ventricular wall (multi-
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Table 1
Patient characteristics at baseline.
Variables All patients (n = 61)
Age (years) 57 ± 12
Gender (M/F) 18/43
Extra-cardiac sarcoidosis present 54 (89)
Hypertension 14 (23)
Diabetes mellitus 14 (23)
CAD 2 (3)
Dyslipidemia 23 (37)
Smoking
Non-smoker 49 (80)
Ex-smoker 6 (10)
Current smoker 6 (10)
Cardiac phenotype (by echocardiography)
Normal 29 (47)
Septal thinning 25 (41)
DCM-like 17 (28)
Clinical data
Heart rate (beats/min) 71 ± 14
NYHA class
I 33 (54)
II 17 (28)
III  9 (15)
IV 2 (3)
Electrical abnormalities
Ventricular arrhythmias 14 (23)
Non-sustained VT 11 (18)
VT/VF 8 (13)
Advanced heart block 24 (39)
Sick sinus syndrome 1 (2)
AF 7 (11)
Supraventricular tachycardia 1 (2)
Laboratory data
Hemoglobin (g/dl) 13 ± 1.7
Serum creatinine (mg/dl) 0.8 ± 0.3
Triglyceride (mg/dl) 138 ± 72
Total cholesterol (mg/dl) 205 ± 35
Brain natriuretic peptide (pg/ml) 325 ± 515
Echocardiographic parameters
LVEF (%) 50 ± 16
LVDs (mm) 37  ± 12
LVDd (mm)  52 ± 8
LAD (mm)  35 ± 6
Positive cardiac biopsy 10 (16)
Ga  scintigraphy (positive/negative) 18/16
DE-MRI (yes/no) 26/11
Drugs
-Blockers 27 (44)
ACE-I/ARBs 33 (54)
Statins 17 (28)
Amiodarone 4 (7)
Results are presented as either mean ± SD or number of patients (%). ACE-I,
angiotensin-converting enzyme inhibitors; AF, atrial ﬁbrillation; ARBs, angiotensin
receptor blockers; BNP, brain natriuretic peptide; CAD, coronary artery dis-
ease; DCM, dilated cardiomyopathy; DE-MRI, delayed enhancement on magnetic
resonance imaging; Ga, gallium; LAD, left atrial dimensions; LVDs/LVDd, end-
systolic/end-diastolic left ventricular dimensions; LVEF, left ventricular ejectionle  small white arrows) in a 41-year-old male patient with sustained ventricular
achycardia and diagnosed with CS on the background of a pre-existing pulmonary
arcoidosis.
rea between April 2002 and March 2012. Their clinical data were
btained from the detailed database of our department at Tohoku
niversity Hospital, including demographic, clinical, laboratory,
maging, procedural, and interventional data. We  examined the
ssociation between baseline data and the presence of VA (NSVT,
T, and VF) at presentation and on follow-up.
iagnostic criteria
The revised guidelines for diagnosis of CS from the Japanese
inistry of Health and Welfare were used [9]. The diagnosis of CS
as made either directly by endomyocardial biopsy, or indirectly
y detection of clinical CS manifestations in the presence of extra-
ardiac sarcoidosis. Beside clinical history, ECG ﬁndings and cardiac
maging tests, including echocardiography, scintigraphy, and MRI
ere used for this purpose.
VA were detected either by ECG monitoring during admission
r later diagnostic evaluation with 12-lead ECG or Holter ECG. VA
ere deﬁned as 3 or more consecutive beats of ventricular origin,
t a rate of more than 100 beats/min [10], detected by any of the
odalities mentioned above, and thus including NSVT, VT, and VF.
eats of ventricular origin not fulﬁlling these conditions were not
ncluded.
tudy outcomes
We  retrospectively examined the baseline clinical variables,
ncluding age, gender, presence of extra-CS, heart rate, New York
eart Association (NYHA) class, brain natriuretic peptide level
BNP), and left ventricular ejection fraction (LVEF) of our CS pop-
lation. The primary endpoint was the occurrence of VA and the
econdary endpoint was a composite of VA, heart failure (HF) hos-
italizations, and cardiovascular mortality.
RI  protocolCardiac MRI  (Fig. 1) was performed before starting corticoste-
oid therapy and after patients had become clinically stable. We
sed the standard protocol for cardiac MRI  in our institution [11],fraction; NYHA, New York Heart Association; VF, ventricular ﬁbrillation; VT, ven-
tricular tachycardia. The results on Ga scintigraphy were obtained from 34 patients
only. The results on DE-MRI were obtained from 37 patients without device therapy.
and ECG-gated magnetic resonance (MR) images were obtained
in all patients during breath-holding on a 1.5-T imager (Magne-
tom Vision, Siemens Medical Solutions, Erlangen, Germany; Achiva,
Philips Medical Systems, Best, The Netherlands) using a body array
coil (Siemens) or a 5-channel cardiac coil (Philips). To evaluate LV
anatomy, cine MR  images of the LV in one horizontal, one vertical-
long, and 5 short-axis slices were obtained. Images from DE-MRI
using inversion-recovery-prepared gradient-echo sequence were
acquired 10–15 min  after the injection of gadopentetate dimeg-
lumine (0.15 mmol/kg) in the same plane as cine imaging with
the Siemens Scanner or in 10 horizontal, 10 vertical-long, and 20
short-axis slices with the Philips scanner. The acquisition param-
eters of the DE-MRIs were 3.7–7.5/1.2–3.4; ﬂip angle, 15◦; ﬁeld
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Fig. 2. Ventricular arrhythmia-free survival. Ventricular arrhythmia-free survival
Unadjusted Cox proportional hazard analysis showed that among
multiple variables beside DE-MRI, only the presence of impaired
LVEF carried a signiﬁcant risk for the occurrence of composite50 M.A. Shafee et al. / Journal o
f view, 380 mm;  matrix, 182–224 × 139–256; and slice thickness,
 mm.  The inversion time (200–300 ms)  was adjusted to null signal
rom normal myocardium. MRI  was performed in 37 patients as the
emaining 24 patients had implanted metal devices. DE-MRIs were
onﬁrmed by the consensus of 2 experienced radiologists blinded
o patient outcome.
tatistical analysis
Continuous variables are expressed as mean ± SD. Categori-
al data are presented as percentage and frequency. Differences
etween groups were compared by Student t-test (for normally
istributed variables) and Mann–Whitney test (for non-normally
istributed variables) for continuous variables. The chi-square test
as used for categorical variables and the Fisher exact test for those
nstances in which the expected cell count was <5. Event rates of
ndpoints are expressed as unadjusted Kaplan–Meier estimates
nd a Cox proportional hazard test was used for the interaction
etween patient characteristics and endpoints. All statistical tests
ere 2-tailed, and a p-value < 0.05 was considered to be statisti-
ally signiﬁcant. All analysis was performed using SPSS software
version 18, SPSS, Chicago, IL, USA).
esults
The clinical characteristics of the 61 patients with CS are shown
n Table 1. They were characterized by middle-age with major-
ty of them being females, and 89% of them had extra-cardiac
nvolvement of sarcoidosis, with the rest being diagnosed based
n histological criteria of endomyocardial biopsy. The prevalence
f hypertension, diabetes mellitus, coronary artery disease, and
moking was relatively low. No clinical or echocardiographic evi-
ence of structural heart disease was noted in approximately half of
he patients (47%), with evidence of characteristic septal thinning
oted in 41% of patients and DCM-like phenotype noted in 28% of
hem.
Most of the patients were in NYHA class I (54%) or II (28%), but
ome patients were in class III (15%) or IV (3%). Advanced heart
lock was the most common electrical abnormality encountered
t baseline (39%), and VA collectively was the second most com-
on  electrical abnormality (23%), where NSVT was noted in 18%
nd VT/VF in 13%. Laboratory and echocardiographic data were
ithin normal range except for mildly elevated BNP level (Table 1).
mportantly, DE-MRI was noted in 70% of the 37 CS patients tested,
hereas a positive gallium (Ga) scintigraphy was noted in 50%
f the 34 patients tested at presentation and ﬁnally only 16% of
atients had a positive cardiac biopsy. Amiodarone was  adminis-
ered to 7% of the patients.
Table 2 shows the baseline characteristics of the 37 patients with
RI  data according to presence or absence of DE-MRI. There was
o signiﬁcant difference in baseline characteristics between the 2
roups despite the expected trends of a higher NYHA class, a higher
NP level, and a larger LV in patients with DE-MRI. Interestingly, in
his sub-population LVEF was preserved and showed no difference
n LVEF between the 2 groups.
The variables of interest for possible association with VA at
aseline are shown in Table 3. Age, gender, the presence of extra-
S, heart rate, worse NYHA class, and BNP were not signiﬁcantly
ssociated with VA. In contrast, echocardiographic parameters
f impaired systolic LV function, as assessed by LVEF and end-
ystolic/end-diastolic dimensions (LVDs/LVDd), were signiﬁcantly
ssociated with VA (p = 0.01, 0.02, and 0.04, respectively). Impor-
antly, the presence of DE-MRI also showed a signiﬁcant association
p < 0.05) and its absence carried 100% negative predictive value for
A at baseline.rate tended to be worse in cardiac sarcoidosis patients with delayed enhancement
on cardiac magnetic resonance imaging (DE-MRI) compared with those without it
(log rank test, p = 0.12).
In the mean follow-up period of 45 months, VA-free survival
rate tended to be worse in CS patients with DE-MRI compared
with those without it (p = 0.12) (Fig. 2). Furthermore, composite
endpoint-free survival rate was signiﬁcantly worse in CS patients
with DE-MRI compared with those without it (p < 0.05) (Fig. 3).Fig. 3. Composite endpoint-free survival. Composite endpoint-free survival was
signiﬁcantly worse in cardiac sarcoidosis patients with delayed enhancement on
cardiac magnetic resonance imaging (DE-MRI) compared with those without it (Log
rank test, p = 0.03).
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Table  2
Patient characteristics by the presence or absence of delayed enhancement on magnetic resonance imaging (n = 37).
Variables DE-MRI (n = 26) No DE-MRI (n = 11) p-Value
Age (years) 56 ± 15 53 ± 12 0.64
Gender (M/F) 8/18 4/7 0.51
Extra-cardiac sarcoidosis 22 (84) 8 (72) 0.33
Heart rate (beats/min) 73 ± 12 65 ± 17 0.16
Septal thinning (present/absent) 7/14 0/7 0.09
DCM-like phenotype 5 (19) 0 (0) 0.15
NYHA class
I 17 (65) 9 (82) 0.20
II 8  (31) 1 (9)
III 0 (0) 1 (9)
IV 1 (4) 0 (0)
BNP (pg/ml) 133 ± 192 112 ± 178 0.76
Echocardiographic parameters
LVEF (%) 56 ± 14 57 ± 8 0.88
LVDd (mm) 50 ± 8 47 ± 4 0.34
LVDs  (mm) 34  ± 9 27 ± 10 0.052
Cardiac biopsy (positive/negative) 3/14 0/4 0.51
Ga  scintigraphy (positive/negative) 6/7 0/4 0.13
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Aesults are presented as either mean ± SD or number of patients (%). BNP, brain
agnetic resonance imaging; Ga, gallium; LVDs/LVDd, end-systolic/end-diastolic le
ssociation. The results on Ga scintigraphy were obtained from 34 patients only.
ndpoint [Hazard ratio (HR) 0.35; 95%CI, 0.16–0.75; p = 0.01], but
ot for that of VA (HR, 0.52; 95%CI, 0.20–1.34; p = 0.17) (Table 4).
he long-term prognosis, including VA and composite endpoint,
as comparable between the CS patients who underwent MRI  test
n = 37) and those who did not (n = 24) (p = 0.27, and 0.21 respec-
ively).
iscussion
The novel ﬁnding of the present study is that in addition to
educed LV systolic function, DE-MRI is a signiﬁcant prognostic
actor of serious VA and poor outcome in patients with CS.
revalence and diagnosis of CS
The prevalence of sarcoidosis is relatively high in Japan [2]
nd the incidence of cardiac involvement is also high [12], reach-
ng ∼60% of sarcoidosis patients in some series [13]. This offers a
nique chance to study various unstudied aspects of this disorder.
lthough it was previously shown that the majority of western CS
atients are young adults between the ages of 20–40 years without
able 3
atient characteristics by the presence or absence of ventricular arrhythmias at baseline.
Variables Ventricular arrhythmia (n = 14) 
Age (years) 57 ± 13 
Gender (M/F) 6/8 
Extra-cardiac sarcoidosis 10 (71) 
Heart  rate (beats/min) 71 ± 11 
Septal thinning (present/absent) 10/3 
DCM-like phenotype 7 (50) 
NYHA  class
I 7 (50) 
II  4 (29) 
III  2 (14) 
IV  1 (7) 
BNP (pg/ml) 434 ± 656 
Echocardiographic parameters
LVEF (%) 40 ± 17 
LVDd  (mm) 57 ± 12 
LVDs  (mm)  45 ± 12 
Ga  scintigraphy (positive/negative) 7/14 
DE-MRI (yes/no) 8/0 
esults are presented as either mean ± SD or number of patients (%). BNP, brain natriu
agnetic resonance imaging; Ga, gallium; LVDs/LVDd, end-systolic/end-diastolic left ven
ssociation. The results on Ga scintigraphy were obtained from 34 patients only. The resuretic peptide; DCM, dilated cardiomyopathy; DE-MRI, delayed enhancement on
tricular dimensions; LVEF, left ventricular ejection fraction; NYHA, New York Heart
a deﬁnite sex predominance [5],  the present study shows that the
majority of the Japanese CS patients are middle-aged females, a
consistent ﬁnding with the previous studies in Japan [3,14].  These
results suggest some racial differences in demographic characteris-
tics of CS patients that might extend to presentation and prognosis
of the disorder. Most of the CS patients in the present study were
diagnosed in conjunction with involvement of other organs, again,
a consistent ﬁnding with a previous study in Japan [15].
Almost half of CS patients in the present study showed no
evidence of structural cardiac abnormality when assessed by
echocardiography with a similar prevalence rate as in western
studies with 14–31% prevalence rate [16,17], thus highlighting the
limited sensitivity of echocardiography in this subset of CS patients
[18]. In CS patients, the usual echocardiographic abnormality in
our study was  characteristic septal thinning, which was a part of
LV being globally affected, and depressed LVEF characteristic of a
DCM-like picture noted in half of them. It was difﬁcult to distin-
guish this abnormality from the idiopathic form [2,12,18], which
was a common morphological ﬁnding in our cohort.
Indeed, echocardiography has a low speciﬁcity for diagnosis
of CS [18], and its main value lies in its ability to predict poorer
No ventricular arrhythmia (n = 47) p-Value
57 ± 12 0.94
12/35 0.31
39 (82) 0.44
71 ± 15 0.95
15/23 0.02
13 (27) 0.19
26 (55) 0.82
13 (28)
7 (15)
1 (2)
291 ± 466 0.37
52 ± 14 0.01
51 ± 7 0.04
35 ± 11 0.02
11/12 0.31
18/11 0.04
retic peptide; DCM, dilated cardiomyopathy; DE-MRI, delayed enhancement on
tricular dimensions; LVEF, left ventricular ejection fraction; NYHA, New York Heart
lts on DE-MRI were obtained from 37 patients without device therapy.
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Table 4
Unadjusted hazard ratios for ventricular arrhythmias and composite endpoint.
Variables Ventricular arrhythmias Composite endpoint
HR (95%CI) p-Value HR (95%CI) p-Value
Age 1.01 (0.96–1.04) 0.79 1.01 (0.97–1.03) 0.87
Gender 1.04 (0.37–2.94) 0.93 0.91 (0.38–2.19) 0.84
LVEF  0.52 (0.20–1.34) 0.17 0.35 (0.16–0.75) 0.01
0.09
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tVA  at baseline 2.24 (0.87–5.77)
I, conﬁdence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; VA
rognosis of CS patients, as LV dilatation is an established predic-
or of mortality [3].  Although an appearance similar to hypertrophic
ardiomyopathy (HCM) has been described in some cases [19], we
id not come across any patient with such a phenotype in the
resent study.
entricular arrhythmias in CS patients
It seems that the prevalence of VA in CS patients has tended
o increase in recent registries and observation studies compared
ith previous ones. There may  be two reasons for this. First, the
umber of survivors with out-of-hospital cardiac arrest (OHCA)
as been increasing owing to early deﬁbrillation intervention in
any countries [20,21]. Second, the use of Holter ECG monitor-
ng and exercise stress testing for CS patients has been increasing
22]. Although both advanced atrioventricular block and VT are
ostulated as major causes of OHCA in CS patients [23], it was
eported that sustained VT associated with LV enlargement by
chocardiography was an independent predictor of all-cause mor-
ality in Japanese CS patients [3].  This highlights the importance
f establishing risk-stratifying criteria for VT with a high-degree of
ensitivity and speciﬁcity to prevent OHCA.
atients with DE-MRI
In the sub-population with MRI  data, it is interesting to see
hat there are no signiﬁcant differences in baseline characteris-
ics between patients with DE-MRI and those without it. More
mportantly, LVEF, which is the most important confounding factor
ssociated with the presence of DE-MRI, was preserved and com-
arable between the 2 groups, suggesting that any detected value
f DE-MRI is independent of the effect of LV function.
actors associated with VA and poor outcome in CS patients
In the present study, in order to elucidate the prognostic factors
hat could predict the occurrence of VA and poorer outcome in CS
atients, we ﬁrst analyzed the association between various baseline
haracteristics with VA, both at presentation and longitudinally on
ollow-up, as our primary endpoint. Although higher resting heart
ates are being studied extensively as a marker of poor outcome in
schemic patients [24], this has not been the case in our CS cohort.
lso, despite that we found a signiﬁcant association between the
resence of VA at baseline and multiple surrogates for compro-
ised LV systolic function (e.g. septal thinning, lower LVEF, and
arger LVDs/LVDd), in agreement with previous studies [25–27],  an
mpaired LV systolic function was not found to signiﬁcantly predict
A incidence during the follow-up period of the study, despite an
pparent trend. This may  be related to both the limited number of
atients with impaired LV function and the limited number of VA
vents on follow-up in the present study.On the other hand, by using cardiac magnetic resonance imag-
ng (CMRI) [28,29],  we were able to demonstrate that DE-MRI was
igniﬁcantly associated with VA at baseline and showed a strong
rend toward higher VA events on follow-up by Kaplan–Meier 1.69 (0.78–3.68) 0.18
ricular arrhythmias.
estimates. This ﬁnding also supports the role of CMRI as a risk strat-
iﬁcation method for VA and adverse prognosis in various forms of
structural heart disease, owing to its unique ability to accurately
detect and delineate myocardial ﬁbrosis, the presence and extent
of which have become well-established markers of poorer progno-
sis [30–35].  Bello et al. reported that scar burden was a signiﬁcant
predictor of VT inducibility, whereas LVEF was not [30]. It has
been recently shown that patients with advanced cardiomyopa-
thy and implantable cardioverter-deﬁbrillators (ICDs) with proven
myocardial ﬁbrosis by DE-MRI have a high likelihood of appropriate
ICD therapy [36]. Although scar-based-reentry has been thought
to account for VA only in patients with ischemic cardiomyopa-
thy (ICM), accumulating evidence suggests that reentry appears to
play a major role in the mechanism of sustained monomorphic VT
in this patient population [37]. Furthermore, it has been recently
demonstrated that programmed electrical stimulation predicts
appropriate ICD therapy used for primary prevention of SCD only in
patients with evidence of cardiac involvement on CMRI or positron
emission tomography [38], suggesting the possible importance of
DE-MRI for risk stratiﬁcation for VA and SCD in CS patients.
The extent of myocardial ﬁbrosis was also shown to predict
poorer outcome, in terms of cardiovascular morbidity and mortal-
ity, in various forms of structural heart disease, whether detected
by histopathology [39] or DE-MRI [32,33],  and was  even related to
poor prognosis in the general population [40]. This notion is sup-
ported by the present ﬁnding that DE-MRI could predict poorer
outcome for morbidity and mortality in CS patients.
It would be more important to point out that all CS patients with-
out DE-MRI could have an uneventful course and that this perfect
negative predictive value not only enforces the role of DE-MRI in
prediction of adverse outcome in this population but also stands
out as a unique diagnostic criterion for CS in patients with extra-
cardiac involvement. The present ﬁndings may  be useful for the
revision of a major diagnostic criterion by the Japanese Ministry of
Health and Welfare [9].
Study limitations
Several limitations should be mentioned for the present study.
First, our study has the inherent limitations of retrospective anal-
ysis. Thus, the present ﬁndings should be conﬁrmed in a future
prospective study. Second, not all CS patients underwent CMRI test.
This was  inevitable as device implantation was  the reason for con-
traindication in most cases without CMRI study. However, since the
clinical characteristics and long-term prognosis were comparable
between the patients who  underwent CMRI study and those who
did not, the present ﬁndings may  not be biased on this point. Third,
the number of CS patients who  underwent the test was relatively
small. Thus, the present ﬁnding remains to be conﬁrmed in a future
study with a large number of patients.
Fourth, the present study included the patients who had been
diagnosed more than 10 years ago, when it was  insufﬁcient to
search for extra-CS. This may  have caused the slightly high rate
of isolated CS. Thus, the present ﬁnding remains to be conﬁrmed in
a future study with a large number of patients.
f Card
C
m
p
p
p
D
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[M.A. Shafee et al. / Journal o
onclusions
In the present study, we were able to demonstrate that a pri-
ary presentation with VA is relatively common in Japanese CS
atients and that the presence of DE-MRI is a strong and signiﬁcant
redictor of poor outcome in general and VA in particular in this
atient population.
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